2023 – September Seminar + Statutes Voting

Role of nuclear medicine in the management of brain tumors and new therapeutic approaches – 23 September 2023

1 RIZIV/INAMI accreditation for nuclear medicine physicians is available for BELNUC members only.

Brain tumors in the nuclear medicine department: imaging and theranostics.

Glioblastoma appears to be the most aggressive and also, unfortunately, the most frequent primary brain tumor. The worldwide incidence of glioblastoma is less than 10 per 100,000 people and represents approximately 50–60% of gliomas and 15% of all primary brain tumors in adults. A good and fast diagnosis is therefore of utmost importance, and that is where we as a nuclear medicine department play a key role. How can we help our colleagues neurosurgeons, and what is the best way to interpret and analyse 18F-FET-PET/CT images? And can other tracers, such as, 68Ga- Dotatate, be important in the diagnosis of brain tumors?

The recent progress in nuclear medicine development has generated a new promising arsenal for glioblastoma therapy. This has been mainly driven by biotechnologies such as radioimmunotherapy, radiopeptide therapy, and radionanoparticles. We will get a sneak peak into the first experiences with these new targeted therapies.


Moderators: Vanessa Schelfhout and Sophie Bourgeois

09:00 – 09:30 Glioblastoma work-up and collaboration with the nuclear medicine department.
Wietse Geens, MD, PhD, Neurosurgery/ neuro-oncology dept. UZ Brussel
09:30 – 10:00 Use of 18F-FET-PET/CT and 68Ga-Dotatate-PET/CT in the management of brain tumors: practical use and pitfalls.
Donatienne Van Weehaeghe, MD, PhD, Dept of Nuclear medicine, UZ Gent
10:00 – 10:30 Berak
10:30 – 11:00 Use of 177Lu-NeoB for therapy of glioblastoma.
Simone Dalm, PhD, Assistant Professor and PI of radiotracer interactions at the dept. of nuclear medicine and radiology of Erasmus MC Rotterdam
11:00 – 12:15 Extraordinary General assembly with M. Marcelis (Notaris)

Registration Link:BELNUC Seminar September & Statutes voting